This article was originally published on this site
Anthera Pharmaceuticals Inc. (ANTH) had a rough trading day for Friday July 13 as shares tumbled 13.64%, or a loss of $-0.0135 per share, to close at $0.09. After opening the day at $0.10, shares of Anthera Pharmaceuticals Inc. traded as high as $0.10 and as low as $0.09. Volume was 107,026 shares over 49 trades, against an average daily volume of 1.81 million shares and a total float of 26.18 million.
As a result of the decline, Anthera Pharmaceuticals Inc. now has a market cap of $2.24 million. In the last year, shares of Anthera Pharmaceuticals Inc. have traded between a range of $2.97 and $0.07, and its 50-day SMA is currently $0.25 and 200-day SMA is $1.13.
For a complete fundamental analysis of Anthera Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for ANTH.
Still paying commissions on stock trades? Equities.com now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by https://www.equities.com/trading
Anthera Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapeutics to treat serious diseases.
Anthera Pharmaceuticals Inc. is based out of Hayward, CA and has some 21 employees. Its CEO is John Thompson.
Anthera Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
To get more information on Anthera Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ANTH’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer